Morgan Stanley Chemomab Therapeutics Ltd. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Morgan Stanley holds 117,160 shares of CMMB stock, worth $156,994. This represents 0.0% of its overall portfolio holdings.
Number of Shares
117,160
Previous 104,400
12.22%
Holding current value
$156,994
Previous $210,000
39.52%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding CMMB
# of Institutions
18Shares Held
3.72MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.74MShares$2.33 Million0.06% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3900KShares$1.21 Million0.26% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3578KShares$774,9090.12% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$285,4890.03% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$41,8620.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $15.3M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...